This discovery could lead to better prenatal vaccines
![A pregnant student is seen during a demonstration to demand global action on climate change as part of the "Fridays for Future" movement in Rio de Janeiro, Brazil March 15, 2019. REUTERS/Sergio Moraes - RC1A4E591D90](https://assets.weforum.org/article/image/large_cz_7-VWTavpcer0YQ8iq6N1szGYMYLnTlqOIZSS50RA.jpg)
A new route for antibodies. Image: REUTERS/Sergio Moraes - RC1A4E591D90
![A hand holding a looking glass by a lake](/uplink.jpg)
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:
Education
A newly identified cellular process could lead to safer and more effective vaccines that protect pregnant women and newborns from dangerous infections, researchers say.
A new study in Cell describes a previously unidentified route for antibodies to transfer from the mother to the fetus, illuminating a potential way to capitalize on the process to control when and how certain antibodies are shared.
“It’s always been assumed that the types of maternal antibodies that cross over the placenta to the fetus, all antibodies had the same chance of transferring to fetus,” says senior author Sallie Permar, a professor of pediatrics and member of the Duke University Human Vaccine Institute.
“This meant there was no way we could direct certain antibodies across the placenta and to the baby,” Permar says. “Our study found that there seems to be a code on the antibody that determines which antibodies will more effectively transfer across the placenta.”
Permar and colleagues studied two populations of pregnant women in the United States and Malawi infected with HIV, known to inhibit the transfer of antibodies to the fetus—and not just HIV antibodies. The researchers say this feature provided a unique circumstance to explore a little-understood process with implications for numerous common pathogens, including tetanus, pertussis, influenza, and others.
The researchers identified a sugar molecule that interacts with placental receptors, an interaction that had previously not been known to be involved in the antibody transfer process. The finding was corroborated in healthy women by another research team publishing in the same issue of Cell.
“We have shown that the efficiency of antibody transfer across the placenta is differentially regulated,” Permar says. “This insight could improve the design of vaccines for a variety of infectious diseases to improve the transplacental antibody transfer to the fetus.”
“Our findings provide a roadmap of how antibodies cross the placenta to the baby,” says lead author David Martinez, a PhD student. “We hope our results will be useful for developing antibody therapeutics that protect infants against infectious diseases in early life.”
The National Institute of Child Health and Human Development and the National Institute of Allergy and Infectious Diseases partially funded the work.
Don't miss any update on this topic
Create a free account and access your personalized content collection with our latest publications and analyses.
License and Republishing
World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.
The views expressed in this article are those of the author alone and not the World Economic Forum.
The Agenda Weekly
A weekly update of the most important issues driving the global agenda
You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.
More on Education and SkillsSee all
Jeff Maggioncalda
June 21, 2024
Chun Yin Mak
June 18, 2024
Rahmin Bender-Salazar, Breanne Pitt and Christian Roth
June 13, 2024
Mark Muckerheide
May 21, 2024